Abstract: Novel crystalline forms of molnupiravir, including crystalline Forms I and II, which are crystalline forms of uridine 4-oxime 5?-(2-methylpropanoate), may be useful as antiviral agents, specifically as antiviral treatments for infections caused by Eastern Equine Encephalitis Virus (EEEV), Western Equine Encephalitis Virus (WEEV), and Venezuelan Equine Encephalitis Virus (VEEV), Chikungunya fever virus (CHIK), Ebola virus, influenza virus, respiratory syncytial virus (RSV), Zika virus, and coronaviruses, such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and, most recently, SARS-CoV-2 (also known as 2019-nCoV).

Abstract: An exemplary system and method for a head-worn device for augmenting speech therapy or mitigating Parkinson's effect or other speech-impairing conditions by providing haptic feedback, vibratory feedback, audio feedback, or other stimulations to a wearer by isolating and analyzing vocal/speech output of the user for signal-associated assessment, including, e.g., based on timing, direction, loudness, and/or speaking rate. The haptic biofeedback and/or acoustic/vibratory feedback are beneficially provided to the wearer when (i) certain minimum threshold targets, e.g., relating to the user's loudness or speech rate are not met or (ii) when certain thresholds are exceeded, e.g., for loudness, intensity, or speech rate. The system and method can additionally isolate a detected speech or sound and determine if it is from the user. As a signal-assessment analysis system and method, the implementation can be performed with minimal computation power or resources, e.g.

Abstract: An activity-based nanosensor composition for detecting protease activity comprising a cleavable detectable substrate and methods of use are disclosed.

Abstract: CXCR4 antagonists and pharmaceutical formulations thereof are disclosed. The compounds and pharmaceutical formulations disclosed herein can be used to antagonize the CXCR4 pathway for mobilizing stem cells or treating a condition, disorder, or disease associated with the CXCR4 pathway. Exemplary conditions, disorders, and diseases relevant to this disclosure include HIV infections, WHIM syndrome, Waldenström macroglobulinemia, chronic neutropenia, primary immune-deficiency, aplastic anemia, hypoplastic myelodysplastic syndrome, acute respiratory distress syndrome (ARDS), ankylosing spondylitis, autoimmune diseases, and cancers.

Abstract: Compositions and methods for improving embryo development, treating idiopathic male factor infertility, and enabling infertile/sub-fertile/sterile men to father their own genetic offspring are provided. Typically, the methods include administering into a male or female gamete or fertilized embryo an effective amount of a compound that increases bioavailability of a TET protein to improve development of an embryo resulting from fertilization of the female gamete by a male gamete. The compound can be administered into the gamete or embryo before, during, or after fertilization. The compound can be administered by an injection such as intracytoplasmic injection. The compound and the male gamete can be administered in combination by intracytoplasmic sperm injection. Methods of making male gametes, and methods of modifying the genome of a male gamete or embryo using an effective amount of a gene editing composition to correct a gene mutation or anomaly in the genome thereof are also provided.

Abstract: In certain embodiments, this disclosure relates to VIP and VIP agonists, optionally conjugated to nanoparticles, for use in methods of treating inflammatory T cell-mediated diseases or conditions, e.g., treating or preventing GvHD. In certain embodiments, this disclosure relates to methods of pulmonary administration of VIP and VIP agonists, optionally conjugated to nanoparticles. In certain embodiments, this disclosure contemplates nanoparticles disclosed herein.

Abstract: Provided herein are novel reprogrammed smooth muscle cells (rSMCs) and methods of making and using the cells for the treatment of ischemia. The rSMCs are produced by culturing a fibroblast with an all-trans-retinoic acid (ATRA) under conditions that produce the rSMC from the fibroblast, wherein the fibroblasts are genetically modified to overexpress myocardin. The rSMCs offer advantages over currently available regenerative vascular therapies by promoting vascular perfusion in a recipient subject. In particular, the rSMCs can increase neovascularization of both small and large vessels.

Abstract: Stretchable condition-monitoring biopatch devices are disclosed. The stretchable condition-monitoring biopatches may include an elastomer layer. The elastomer layer may adhere to the skin without use of an adhesive. The devices described herein may include stretchable electrodes configured to sense physiological potentials from the patient or subject. The device may include a stretchable circuit board. The stretchable electrodes may be in electrical communication with the stretchable circuit board via stretchable circuits. Methods for providing machine-learning neural networks are disclosed. These methods may include convolution neural networks that incorporate inception-type convolution units that may classify and diagnose conditions based on signals detected by the condition-monitoring biopatches.

Abstract: An apparatus for spoofing attack detection in a wireless system and a method of operation thereof. The apparatus includes a multi-antenna RF array, a beamformer, a preprocessor and a machine learning-based detector. The array produces signals in response to an RF signal from a transmitter having one or more transmitter beam patterns. The beamformer combines the signals using a receiver beam pattern to produce a received signal. The preprocessor produces feature vectors of an RF fingerprint, where a component of a feature vector is a strength of the received signal for a measured beam pattern pair, the beam pattern pair having a transmitter beam pattern and a receiver beam pattern, or a designated value for an unmeasured beam pattern pair. The detector is configured to detect a spoofing attack from an incomplete feature vector that has at least one component corresponding to an unmeasured beam pattern pair.

Abstract: This disclosure relates to modulators of liver receptor homologue 1 (LRH-1) and methods of managing disease and conditions related thereto. In certain examples, modulators are derivatives of hexahydropental ene. In certain examples, this disclosure relates to methods of treating or preventing cancer, diabetes, or cardiovascular disease by administering an effective amount of a hexahydropentalene derivative disclosed herein.

Abstract: A smartphone-based hemoglobin (Hgb) assessment application quantitatively analyzes pallor in patient-sourced photos using image analysis algorithms to enable a noninvasive, accurate quantitative smartphone app for detecting anemia. A user takes a photo of his/her fingernail beds using the app and receives an accurate displayed Hgb level. Since fingernails do not contain melanocytes, the primary source of color of these anatomical features is blood Hgb. At the same time, quality control software minimizes the impact of common fingernail irregularities (e.g. leukonychia and camera flash reflection) on Hgb level measurement. Metadata recorded upon capturing the image is leveraged for determining a users' Hgb level thereby eliminating the need for external equipment. A personalized calibration of image data with measured Hgb levels improves the accuracy of the application.

Abstract: This disclosure relates to methods of preserving mesenchymal stromal/stem cells (MSCs) for use in clinical applications. In certain embodiments, this disclosure relates to methods of preserving MSCs comprising mixing MSCs with interferon-gamma prior to cryopreserving, freezing, or cooling the MSCs to a temperature below zero degrees Celsius.

Abstract: This disclosure relates to pentagalloyl glucose compositions and uses in managing microbial infections and compositions related thereto. In certain embodiments, this disclosure relates to compositions of pentagalloyl glucose. In certain embodiments, this disclosure relates to methods of treating or preventing a microbial infection, e.g., an antimicrobial resistant microbial infection, comprising administering to a subject in need thereof an effective amount of pentagalloyl glucose or salt thereof. In certain embodiments, the microbe is bacteria or fungi resistant to one or more antibiotic agents or antifungal agents.

Abstract: Disclosed herein are method of treating hemophilia A in a subject comprising injecting the subject with mesenchymal stromal/stem cells (MSC) modified to express high levels of Factor VIII protein. The MSC are isolated prenatally, at birth, or after the subject's birth. The modified MSC may also express high levels von Willebrand factor protein.

Abstract: Provided herein is a sensitive, quantitative, and scalable targeted proteomics assay of Alzheimer's Disease biomarkers representing neuronal, glial, vasculature and metabolic pathways. The biomarkers are protease-digested peptides selected from biological samples of individuals having normal A? and Tau levels (AT?) and from symptomatic and asymptomatic individuals having low A? and high Tau levels (AT+). The assay uses selective reaction monitoring-based mass spectrometry (SRM-MS) of peptides in the biological samples after digestion.

Abstract: The present disclosure provides a system for treating melioidosis, comprising a first antimicrobial agent comprising trimethoprim at a subinhibitory concentration and a second antimicrobial agent comprising a FolE2 enzyme inhibitor selected from dehydrocostus lactone, parthenolide, or ?-lapachone, wherein the combination of the first antimicrobial agent and the second antimicrobial agent exhibits chemical synthetic lethality against Burkholderia pseudomallei while having minimal effect on commensal bacteria. The subinhibitory concentration of trimethoprim ranges between 5 ?M and 30 ?M. The FolE2 enzyme inhibitor acts as a mechanism-based inhibitor that covalently modifies a catalytic cysteine residue (Cys154) of the FolE2 enzyme. The combination exhibits greater than 90% growth suppression against Burkholderia pseudomallei. Methods for treating melioidosis and identifying antimicrobial drug targets using chemical synthetic lethality screening approaches are also provided.

Abstract: Disclosed are compounds to the treatment of infectious diseases and methods of treating such diseases. The compounds are derivatives of clevudine.

Abstract: This disclosure relates to methods of managing cancer using bis-biguanide compounds, such as alexidine, and pharmaceutical compositions comprising the same. In certain embodiments, this disclosure relates to methods of treating lung cancer comprising administering an effective amount of a bis-biguanide compound to a subject in need thereof. In certain embodiments, this disclosure relates to methods of treating small cell lung cancer comprising administering an effective amount of a bis-biguanide compound to a subject in need thereof. In certain embodiments, the subject is diagnosed with a lung cancer. In certain embodiments, the subject is diagnosed with small cell lung cancer. In certain embodiments, the subject is a human subject.

Abstract: The disclosure relates to chemokine CXCR4 receptor modulators and uses related thereto. The receptor modulators can be formulated to form pharmaceutical compositions comprising the disclosed compounds or pharmaceutically acceptable salts or prodrugs thereof. The compositions may be used for managing CXCR4 related conditions, typically prevention or treatment of viral infections abnormal cellular proliferation, retinal degeneration, inflammatory diseases, or as an immunostimulant or immunosuppressant or for managing cancer and may be administered with another active ingredient such as an antiviral agent or chemotherapeutic agent.

Abstract: This disclosure relates to chimeric compounds and methods for managing neurological conditions. In certain embodiments, the compound comprises a chemical structure of a monoamine reuptake inhibitor conjugated to a chemical structure of a histone deacetylase inhibitor. In certain embodiments, this disclosure relates to methods of treating or preventing a neurological disorder, mental disorder or depression comprising administering an effective amount of a compound disclosed herein to a subject in need thereof.